Bio-Techne Corp (NASDAQ:TECH – Get Free Report)’s stock price gapped up before the market opened on Thursday . The stock had previously closed at $58.88, but opened at $70.23. Bio-Techne shares last traded at $70.2570, with a volume of 17,111,436 shares changing hands.
Key Bio-Techne News
Here are the key news stories impacting Bio-Techne this week:
- Positive Sentiment: Merck KGaA will acquire Bio-Techne for $73 per share in cash, valuing the company at about $11.3 billion and implying a sizable premium to recent trading levels. Article Title
- Positive Sentiment: The deal gives investors a clear takeover price anchor, which typically pulls shares toward the offer price and boosts sentiment around the stock. Article Title
- Neutral Sentiment: The transaction is expected to close in late 2026 or early 2027, subject to shareholder and regulatory approvals, so there is still execution risk before shareholders receive cash. Article Title
- Negative Sentiment: Law firms have already launched shareholder investigations into whether Bio-Techne’s board obtained a fair price, highlighting potential deal-related legal scrutiny and uncertainty. Article Title
Analyst Upgrades and Downgrades
A number of equities analysts have recently weighed in on the stock. Wells Fargo & Company dropped their price target on shares of Bio-Techne from $76.00 to $62.00 and set an “overweight” rating on the stock in a research note on Thursday, May 7th. Stifel Nicolaus set a $50.00 price objective on Bio-Techne in a research report on Thursday, May 7th. TD Cowen restated a “buy” rating on shares of Bio-Techne in a research note on Tuesday. Royal Bank Of Canada set a $62.00 target price on Bio-Techne and gave the stock an “outperform” rating in a research report on Thursday, May 14th. Finally, Evercore set a $50.00 price target on Bio-Techne in a research note on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $65.15.
Bio-Techne Stock Up 19.7%
The firm has a market cap of $11.04 billion, a P/E ratio of 102.15, a P/E/G ratio of 5.42 and a beta of 1.37. The business’s fifty day moving average price is $52.46 and its two-hundred day moving average price is $56.93. The company has a current ratio of 4.49, a quick ratio of 3.18 and a debt-to-equity ratio of 0.10.
Bio-Techne (NASDAQ:TECH – Get Free Report) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $0.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.55 by ($0.02). The business had revenue of $311.42 million during the quarter, compared to analyst estimates of $316.11 million. Bio-Techne had a net margin of 9.05% and a return on equity of 13.57%. The firm’s revenue for the quarter was down 1.5% on a year-over-year basis. During the same period in the previous year, the firm posted $0.56 EPS. As a group, equities research analysts anticipate that Bio-Techne Corp will post 1.66 EPS for the current year.
Bio-Techne Announces Dividend
The business also recently announced a quarterly dividend, which was paid on Friday, May 29th. Shareholders of record on Monday, May 18th were issued a dividend of $0.08 per share. This represents a $0.32 annualized dividend and a yield of 0.5%. The ex-dividend date was Monday, May 18th. Bio-Techne’s dividend payout ratio (DPR) is 46.38%.
Institutional Trading of Bio-Techne
Several large investors have recently made changes to their positions in the stock. Impax Asset Management Group plc bought a new stake in Bio-Techne during the fourth quarter worth approximately $11,468,000. Hollow Brook Wealth Management LLC raised its position in shares of Bio-Techne by 69.7% in the third quarter. Hollow Brook Wealth Management LLC now owns 174,677 shares of the biotechnology company’s stock valued at $9,717,000 after purchasing an additional 71,739 shares during the period. Border to Coast Pensions Partnership Ltd bought a new position in shares of Bio-Techne in the fourth quarter valued at approximately $15,023,000. Principal Financial Group Inc. lifted its stake in shares of Bio-Techne by 316.7% in the fourth quarter. Principal Financial Group Inc. now owns 703,477 shares of the biotechnology company’s stock worth $41,373,000 after buying an additional 534,676 shares during the last quarter. Finally, Jefferies Financial Group Inc. acquired a new stake in shares of Bio-Techne in the third quarter worth $2,428,000. Institutional investors own 98.95% of the company’s stock.
About Bio-Techne
Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.
Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.
Featured Stories
- Five stocks we like better than Bio-Techne
- Getty Images’ OpenAI Deal Gives the Stock a New AI Licensing Story
- Cerebras Systems, Inc: The Next Rags-to-Riches AI Story?
- Micron’s HBM Surge Could Redefine the AI Growth Story
- Qualcomm’s $4B AI Deal Takes Aim at NVIDIA’s Software Moat
Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.
